Global Levonorgestrel-Releasing Intrauterine Device Market 2024-2030

    In Stock

    .

    LEVONORGESTREL-RELEASING INTRAUTERINE DEVICE MARKET

     

    INTRODUCTION

     The levonorgestrel-releasing intrauterine device (LNG-IUD) is a long-term, reversible, and highly effective form of birth control. It is a small, T-shaped device that is inserted into the uterus by a trained health care provider.

     

    The device releases the hormone levonorgestrel, which thickens the cervical mucus to prevent sperm from entering the uterus and fertilizing an egg. It also thins the lining of the uterus to prevent a fertilized egg from implanting in the uterus. The LNG-IUD is effective for up to five years, depending on the brand.

     

    The LNG-IUD is safe and highly effective. It has a failure rate of less than 1%, meaning fewer than 1 out of 100 women will become pregnant during the first year of use.

     

    It is also associated with fewer side effects than other forms of contraception. Some of the potential benefits of the LNG-IUD include lighter, shorter periods, decreased menstrual cramps, and reduced risk of pelvic inflammatory disease.

     

    The LNG-IUD is safe for most women, including those who have never given birth, are breastfeeding, or have a history of sexually transmitted infections.

     

    However, it is not recommended for women who have an existing or recent history of pelvic inflammatory disease or cancer of the reproductive organs. It is also not recommended for women who are at risk of sexually transmitted infections.

     

    The LNG-IUD is an effective and safe option for women who are seeking a long-term, reversible form of birth control. It is important to discuss the risks and benefits of the LNG-IUD with a health care provider to determine if it is the right choice for you.

     

    LEVONORGESTREL-RELEASING INTRAUTERINE DEVICE MARKET SIZE AND FORECAST

     

    Infographic: Levonorgestrel-Releasing Intrauterine Device Market, Levonorgestrel-Releasing Intrauterine Device Market Size, Levonorgestrel-Releasing Intrauterine Device Market Trends, Levonorgestrel-Releasing Intrauterine Device Market Forecast, Levonorgestrel-Releasing Intrauterine Device Market Risks, Levonorgestrel-Releasing Intrauterine Device Market Report, Levonorgestrel-Releasing Intrauterine Device Market Share

     

    The Global  Levonorgestrel-releasing intrauterine device market accounted for $XX Billion in 2023 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2024 to 2030.

     

    LEVONORGESTREL-RELEASING INTRAUTERINE DEVICE MARKET NEW PRODUCT LAUNCH

    Levonorgestrel-releasing intrauterine devices (IUDs) are a form of long-acting, reversible contraception designed to prevent pregnancy. Levonorgestrel IUDs are small, T-shaped devices that are inserted into the uterus by a healthcare provider.

     

    The devices work by releasing a hormone called levonorgestrel into the uterus, which prevents pregnancy by thickening the cervical mucus and making it difficult for sperm to reach an egg. Levonorgestrel IUDs are considered an effective form of contraception, as they have a failure rate of less than 1%.

     

    Levonorgestrel IUDs are available in a variety of brands, including Mirena, Skyla, Liletta, and Kyleena. The devices are manufactured by several companies, including Bayer, Merck, Teva Pharmaceuticals, and Mylan. Each brand of IUD is slightly different, with varying amounts of levonorgestrel and different sizes.

     

    Levonorgestrel IUDs are increasingly popular among women as an effective and convenient form of contraception. The devices can remain in place for up to 5 years and do not require any daily maintenance or monitoring. Additionally, levonorgestrel IUDs do not interfere with sex or other activities, and they can be removed at any time.

     

    Overall, levonorgestrel IUDs are a safe and effective form of contraception that is becoming increasingly popular among women. The devices are manufactured by several companies, including Bayer, Merck, Teva Pharmaceuticals, and Mylan. Levonorgestrel IUDs provide women with a convenient, long-acting form of contraception that does not interfere with their daily lives.

     

    LEVONORGESTREL-RELEASING INTRAUTERINE DEVICE MARKET COMPANY PROFILE

    • Bayer AG
    • Teva Pharmaceutical Industries
    • Actavis Pharma
    • Mylan N.V.
    • Janssen Pharmaceuticals
    • Pfizer Inc.
    • Merck & Co.

     

    THIS REPORT WILL ANSWER FOLLOWING QUESTIONS OF LEVONORGESTREL-RELEASING INTRAUTERINE DEVICE MARKET

    1. How many Levonorgestrel-releasing intrauterine device  are manufactured per annum globally? Who are the sub-component suppliers in different regions?
    2. Cost breakup of a Global Levonorgestrel-releasing intrauterine device  and key vendor selection criteria
    3. Where is the Levonorgestrel-releasing intrauterine device  manufactured? What is the average margin per unit?
    4. Market share of Global Levonorgestrel-releasing intrauterine device  market manufacturers and their upcoming products
    5. Cost advantage for OEMs who manufacture Global Levonorgestrel-releasing intrauterine device  in-house
    6. key predictions for next 5 years in Global Levonorgestrel-releasing intrauterine device  market
    7. Average B-2-B Levonorgestrel-releasing intrauterine device  market price in all segments
    8. Latest trends in Levonorgestrel-releasing intrauterine device  market, by every market segment
    9. The market size (both volume and value) of the Levonorgestrel-releasing intrauterine device  market in 2024-2030 and every year in between?
    10. Production breakup of Levonorgestrel-releasing intrauterine device  market, by suppliers and their OEM relationship

     

    Sl no Topic
    1 Market Segmentation
    2 Scope of the report
    3 Abbreviations
    4 Research Methodology
    5 Executive Summary
    6 Introduction
    7 Insights from Industry stakeholders
    8 Cost breakdown of Product by sub-components and average profit margin
    9 Disruptive innovation in the Industry
    10 Technology trends in the Industry
    11 Consumer trends in the industry
    12 Recent Production Milestones
    13 Component Manufacturing in US, EU and China
    14 COVID-19 impact on overall market
    15 COVID-19 impact on Production of components
    16 COVID-19 impact on Point of sale
    17 Market Segmentation, Dynamics and Forecast by Geography, 2024-2030
    18 Market Segmentation, Dynamics and Forecast by Product Type, 2024-2030
    19 Market Segmentation, Dynamics and Forecast by Application, 2024-2030
    20 Market Segmentation, Dynamics and Forecast by End use, 2024-2030
    21 Product installation rate by OEM, 2023
    22 Incline/Decline in Average B-2-B selling price in past 5 years
    23 Competition from substitute products
    24 Gross margin and average profitability of suppliers
    25 New product development in past 12 months
    26 M&A in past 12 months
    27 Growth strategy of leading players
    28 Market share of vendors, 2023
    29 Company Profiles
    30 Unmet needs and opportunity for new suppliers
    31 Conclusion
    32 Appendix
     
    0
      0
      Your Cart
      Your cart is emptyReturn to Shop